Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefani Spranger

Showing results (31-40 of 86) with videos related to

Pageof 9
Sort By:
The Journal of Clinical Investigation|October 28, 2010
MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptorsMatthias Leisegang, Susanne Wilde, Stefani Spranger, et al.
Journal for Immunotherapy of Cancer|May 16, 2014
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironmentStefani Spranger, Holly K Koblish, Brendan Horton, et al.
Current Opinion in Immunology|April 13, 2013
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironmentThomas F Gajewski, Seng-Ryong Woo, Yuanyuan Zha, et al.
Science Translational Medicine|August 30, 2013
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cellsStefani Spranger, Robbert M Spaapen, Yuanyuan Zha, et al.
Cancer Immunology Research|January 2, 2025
Lung Cancer-Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg-Dependent CD8+ T-cell ExclusionElen Torres-Mejia, Sally Weng, Charlie A Whittaker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2015
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer ImmunotherapyLijie Zhai, Stefani Spranger, David C Binder, et al.
Cancer Immunology Research|May 20, 2016
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder CancerRandy F Sweis, Stefani Spranger, Riyue Bao, et al.
Science Immunology|September 13, 2024
Expansion of tumor-reactive CD8<sup>+</sup> T cell clonotypes occurs in the spleen in response to immune checkpoint blockadeDuncan M Morgan, Brendan L Horton, Vidit Bhandarkar, et al.
Immunity|November 20, 2021
Type I interferon activates MHC class I-dressed CD11b<sup>+</sup> conventional dendritic cells to promote protective anti-tumor CD8<sup>+</sup> T cell immunityEllen Duong, Tim B Fessenden, Emi Lutz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 2010
Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075Stefani Spranger, Miran Javorovic, Maja Bürdek, et al.
Pageof 9

Showing results (31-40 of 86) with videos related to

Sort By:
Pageof 9
The Journal of Clinical Investigation|October 28, 2010
MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptorsMatthias Leisegang, Susanne Wilde, Stefani Spranger, et al.
Journal for Immunotherapy of Cancer|May 16, 2014
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironmentStefani Spranger, Holly K Koblish, Brendan Horton, et al.
Current Opinion in Immunology|April 13, 2013
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironmentThomas F Gajewski, Seng-Ryong Woo, Yuanyuan Zha, et al.
Science Translational Medicine|August 30, 2013
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cellsStefani Spranger, Robbert M Spaapen, Yuanyuan Zha, et al.
Cancer Immunology Research|January 2, 2025
Lung Cancer-Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg-Dependent CD8+ T-cell ExclusionElen Torres-Mejia, Sally Weng, Charlie A Whittaker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2015
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer ImmunotherapyLijie Zhai, Stefani Spranger, David C Binder, et al.
Cancer Immunology Research|May 20, 2016
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder CancerRandy F Sweis, Stefani Spranger, Riyue Bao, et al.
Science Immunology|September 13, 2024
Expansion of tumor-reactive CD8<sup>+</sup> T cell clonotypes occurs in the spleen in response to immune checkpoint blockadeDuncan M Morgan, Brendan L Horton, Vidit Bhandarkar, et al.
Immunity|November 20, 2021
Type I interferon activates MHC class I-dressed CD11b<sup>+</sup> conventional dendritic cells to promote protective anti-tumor CD8<sup>+</sup> T cell immunityEllen Duong, Tim B Fessenden, Emi Lutz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 1, 2010
Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075Stefani Spranger, Miran Javorovic, Maja Bürdek, et al.
Pageof 9